JLK

JLK Inc. (JLK Group) is a South Korean medical AI company specializing in AI-powered imaging diagnosis solutions for stroke and other neurological conditions. The company offers a full-cycle stroke AI solution supporting emergency through treatment phases, analyzing medical images including CT, CTA, CTP, MRI, and MRA to rapidly identify stroke subtypes and guide clinical decision-making. JLK's flagship platform, JLK-AILink, received U.S. FDA 510(k) clearance in February 2025, enabling deployment in American hospitals. Its AI diagnostic systems include tools for CT perfusion analysis, MRI diffusion and perfusion-weighted imaging, and atrial fibrillation-based stroke subtype classification. JLK has over 13 AI solutions covering hemorrhagic and ischemic stroke, giving it a significant competitive edge as it expands globally. The company is publicly listed in South Korea and has deployed its technology in hospitals across India, Korea, and other international markets, positioning itself as a global leader in AI-based medical imaging for cerebrovascular disease.